HOME >> BIOLOGY >> NEWS
Prior caesarean delivery not linked to increased risk of stillbirth

Women with a history of caesarean section deliveries do not have a higher risk of a subsequent stillbirth, according to researchers at Yale School of Medicine and Columbia University.

Yale Obstetrics and Gynecology scientist Mert Ozan Bahtiyar, M.D., presented the findings today at the annual meeting of the Society for Maternal Fetal Medicine, held February 7-12 in Reno, Nevada.

"Caesarean sections have been associated with some pregnancy complications, but when a physician consults a woman with prior caesarean sections about her next pregnancy, stillbirth should not be one of the concerns," said Bahtiyar.

Fetal death or stillbirth is an underappreciated problem, according to Bahtiyar, who said that stillbirths account for more perinatal deaths than do complications of prematurity or sudden infant death syndrome. Some risk factors for stillbirth include history of a prior stillbirth, a mother over the age of 35, smoking, substance abuse, and underlying medical conditions such as diabetes, hypertension or preeclampsia. A previous study by researchers in England found that prior caesarean delivery was also a factor in increased risk of stillbirth.

Bahtiyar and his team decided to confirm the previous study using U.S. data from the Centers for Disease Control and Prevention's combined birth and death certificates from 1995 to 1997. They used a statistical analysis method called Cochran-Mantel-Haenszel to determine the odds of fetal death after prior caesarean section.

"We used a much larger data set of 250,000 patients than the British study, which used 16,000 patients," said Bahtiyar. "We were not expecting different results, but we found that prior caesarean section did not increase the risk of future stillbirth."

Co-authors included Joshua Copel, M.D., Charles J. Lockwood, M.D., and Errol R. Norwitz, M.D., of Yale; and Julian Robinson, M.D., Lambert Lumey, M.D., and Patricia Zybert, M.D., of Columbia.
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
12-Feb-2005


Page: 1 2

Related biology news :

1. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
2. Gene therapy delivery of nerve growth factors reverses erectile dysfunction in animal model
3. New designer lipid-like peptide with lipid nanostructures for drug delivery systems
4. Alcohol use during pregnancy leads to greater risk of extreme preterm delivery
5. BEMA Fentanyl demonstrates substantial transmucosal delivery
6. Little lifesavers -- Nanoparticles improve delivery of medicines and diagnostics
7. Polymers show promise for gene delivery, tissue scaffolds, other biomedical applications
8. Nanoparticles for delivery of prostate cancer treatment
9. LED array signals successful binding of drug-delivery molecules to DNA
10. Pregnancy news -- Preterm delivery risk reduced by high-dose progesterone treatment
11. ResearchChannel expands delivery for its extensive online video library

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Prior caesarean delivery not linked increased risk stillbirth

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: